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Background: The accurate diagnosis of dysplasia or carcinoma within ampullary lesions can be difficult,
but, when possible, identifies patients who require endoscopic or surgical resection, respectively. The role
of endoscopic ultrasound (EUS) in diagnosing these lesions and the degree of dysplasia is unclear.
Methods: Patients with lesions of the ampulla were identified over 5 years. Patients who did not undergo
EUS were compared with those who did.
Results: A total of 27 of 58 (47%) patients were investigated with EUS. Pretreatment diagnoses were
correct in 93% of the EUS group vs. 78% of the no-EUS group. Rates of diagnostic accuracy in low-grade
dysplasia (LGD), high-grade dysplasia (HGD) and adenocarcinoma (ADC) were 72%, 20% and 96%,
respectively, in the no-EUS group, and 93%, 50% and 100%, respectively, in the EUS group. Every
diagnosis of LGD in the EUS group was correct, whereas these diagnoses accounted for the majority of
errors (eight of 13) in the no-EUS group. High-grade dysplasia was frequently misdiagnosed. More
patients were treated by endoscopic resection in the EUS group (12 of 27 vs. five of 31; P = 0.025).
Conclusions: Endoscopic ultrasound increases the accuracy of preoperative diagnosis of ampullary
lesions and is particularly useful in patients with LGD because it permits safe endoscopic management.
Patients with HGD must be reviewed carefully and considered for pancreatoduodenectomy.
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Introduction
Tumours of the ampulla of Vater are uncommon and represent
only 0.2% of gastrointestinal tract tumours.1 Lesions display cel-
lular atypia that progress from low-grade dysplasia (LGD) to inva-
sive adenocarcinoma (ADC).2 Accurate preoperative diagnosis is
essential as the management of dysplastic lesions can be achieved
with endoscopic means, whereas resectable carcinoma requires
pancreaticoduodenectomy.2,3 Furthermore, the identification of
patients with metastatic disease avoids unnecessary surgery and
morbidity. The accurate diagnosis and staging of ampullary
lesions rely heavily upon the interpretation of radiological infor-
mation and biopsy material.4,5 The presence of jaundice may
represent malignant change in an ampullary adenoma, although
benign adenomas are often identified incidentally when jaundice
of other causes is investigated.6 In comparison with computerized
tomography (CT) and magnetic resonance imaging (MRI), endo-
scopic ultrasound (EUS) has the ability to demonstrate in higher
spatial resolution the ampulla, closely related anatomical struc-
tures including lymph nodes, and the interface between the
duodenal wall and pancreas.7,8 For these reasons the sensitivity
and specificity of EUS in performing preoperative tumour (T)
and node (N) staging are superior to those of MRI or CT.9
However, EUS can be a technically challenging procedure and
although it is widely available, is very much operator-dependent.
Dysplastic ampullary adenomas are considered premalignant
although the time to progression remains uncertain. Given that
the management of patients with LGD is better served with local
resection (endoscopic or surgical), EUS is an important tool with
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which to define the degree of dysplasia within ampullary lesions.
This study sought to identify the accuracy of preoperative diag-
nosis and staging in patients with ampullary lesions and, in par-
ticular, to identify which patients benefit most from EUS.
Materials and methods
Patients with ampullary adenomas or adenocarcinomas were
identified from a surgical departmental database and pathology
records. Both sets of records were cross-checked to establish the
suitability of patients for inclusion and to ensure that no patients
were missed. The study period was January 2006 to December
2011. Patients in whom the lesion arose from a location other than
the ampulla were excluded. Presenting complaints, preoperative
investigations, patient demographic details, and data on operative
or endoscopic management, complications and outcome were
recorded. All patients were presented and reviewed at a multidis-
ciplinary meeting (MDT). Tumours were classified using the
tumour–node–metastasis (TNM) classification and dysplasia was
defined as being of low (LGD) or high (HGD) grade. All patho-
logical specimens were analysed by consultant histopathologists
within a specialist hepatopancreatobiliary unit.
Patients were divided into two groups, comprising, respectively,
those in whom preoperative investigations included EUS and
those in whom EUS was not performed. There was no standard
algorithm to investigate or manage these patients. Preoperative
investigations included a combination of CT,MRI and endoscopic
retrograde cholangiopancreatography or oesophagogastroduode-
noscopy. Management comprised endoscopic resection or trans-
duodenal resection for LGD and pancreatoduodenectomy for
HGD and ADC if the patient was considered fit enough. The
preoperative diagnosis was compared with the final pathological
diagnosis to identify sensitivity, specificity, and negative and posi-
tive predictive values. Endoscopic ultrasound was performed after
multidisciplinary review for each patient. Thus, for patients in
both the no-EUS and EUS groups, a preoperative diagnosis
without EUS information was available for comparison with post-
operative findings. The preoperative diagnosis was established
based upon histological findings presented to the MDT; when
tissue for histology was unavailable or the diagnosis was question-
able, the MDT’s diagnosis was based on the interpretation of
radiological and clinical information. The pathological spectrum
included LGD, HGD, carcinoma in situ (Cis) and ADC. Carci-
noma in situ was grouped with HGD. A preoperative diagnosis of
HGDwas treated as a diagnosis of ADC because invasive ADCwas
frequently found within HGD after formal resection10 and because
there is a risk for lymph node metastasis in T1 ampullary
tumours.11
All EUS procedures were performed by a single operator (BSM)
with the patient under conscious sedation administered by the
endoscopist. Linear echoendoscopes (GF-UCT240 and 260-AL5;
Olympus Corp., Tokyo, Japan) were used for all procedures. Intra-
venous buscopan (20 mg) was used to inhibit duodenal peristalsis
during the procedure. A total of 40–80 ml of water was infused
into the duodenum to create negative contrast for ultrasound
imaging. Tissue samples were obtained from a combination of
fine needle aspiration performed with EchoTip® 22-G or 19-G
needles (Cook Medical Inc., Bloomington, IN, USA) and mucosal
biopsies obtained with Radial Jaw® 4 Jumbo Biopsy Forceps
(Boston Scientific Corp., Natick, MA, USA). The samples were
deposited in CytoRich® Red (TriPath Imaging, Inc., Burlington,
NC, USA) prior to cytological analysis.
Data are expressed as the median (range). Continuous variables
were assessed using the Mann–Whitney test and categorical vari-
ables with the chi-squared test or Fisher’s exact test when one or
more frequencies did not exceed 5. Significance was indicated by a
P-value of <0.05 and analyses were performed using paswVersion
18 (SPSS, Inc., Chicago, IL, USA).
Results
A total of 58 subjects were found to meet the inclusion criteria.
Computed tomography was performed in 52 patients, MRI in
six and upper gastrointestinal endoscopy (UGIE) in 51. An EUS
was performed in 27 patients. The median age of the entire
cohort was 67 years (range: 19–85 years). The cohort included 37
men (64%). The final pathological diagnosis was LGD in 23
patients, HGD in three patients, and ADC in 32 patients. In the
latter group, one patient had a malignant neuroendocrine
tumour and the remaining 31 patients had intestinal type ADC
(Table 1).
Both the EUS and no-EUS groups were comparable with
respect to age, gender and presenting complaints (Table 1). A
significantly greater proportion of endoscopic mucosal resections
(EMRs) were performed amongst the EUS group (12 of 27 vs. five
of 31 patients; P = 0.025). To date, none of the patients who
underwent endoscopic resection have developed malignant
tumours. Of the 12 patients in the EUS group in whom curative
resection was attempted, three were identified as having unresec-
table distant disease at operation. The median follow-up was
18 months (range: 1–65 months). Table 1 summarizes manage-
ment strategies and outcomes in the EUS and no-EUS groups.
Accuracy of preoperative investigations
The overall accuracy of the preoperative diagnoses in the no-EUS
and EUS groups is shown in Table 2. Sensitivity, specificity, and
negative and positive predictive values for the diagnosis of LGD,
HGD and ADC in the no-EUS and EUS groups are given in
Table 3.
The 13 patients in the no-EUS group for whom the preopera-
tive diagnosis was found to have been incorrect were identified on
EUS as having LGD (n = 8), HGD (n = 4) or ADC (n = 1). The two
patients in the EUS group for whom the preoperative diagnosis
was found to have been incorrect had been diagnosed with
adenoma (n = 1; the lesion was seen but the tissue obtained for
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pathological assessment was not suitable) and HGD (n = 1).
Excluding the ‘adenoma’, LGD was correctly diagnosed in every
patient in the EUS group. A comparison of pre- and postoperative
diagnoses is provided in Table 2.
A preoperative diagnosis of HGD tended to understage these
lesions: three of five cases were subsequently identified as ADC.
One case was found to represent LGD. Of the cancers, two cases
following resection were classified as T2N0M0, but one was ren-
dered inoperable by peritoneal disease (TxNxM1).
There was a significant difference between the groups in terms
of management. Fewer patients in the EUS group underwent sur-
gical resections and more underwent endoscopic resection (P =
0.025) (Table 1). The numbers of patients undergoing planned
pancreatoduodenectomy, transduodenal resection and EMR,
respectively, were 24, two and five in the no-EUS group, and 12,
three and 12 in the EUS group. Three patients in the EUS group
were found to have inoperable disease at pancreatoduodenectomy
as a result of occult liver metastases or peritoneal disease.
The presence of jaundice was a predictor of malignancy (25 of
32 cases with a bilirubin level of >20 mmol/l; P < 0.001), although
eight patients with a normal bilirubin level received a final diag-
nosis of ADC and a further two were diagnosed with HGD.
Table 1 Summary of presenting features, management and outcomes in the endoscopic ultrasound (EUS) and no-EUS groups
No-EUS group EUS group P-value
Male/female, n 21/10 15/12 0.493b
Age, years, median (range) 69 (19–85) 65 (44–82) 0.596c
Presenting complaint, n Jaundice 18 9 0.082b
Pain 4 3
Incidental finding 8 15
Melaena 1 0
Postoperative diagnosis, n Low-grade dysplasia 10 13 0.470b
High-grade dysplasia 1 1
Adenocarcinoma 20 13
Management, n Resectiona 24 12 0.025b
Transduodenal resection 2 3
Endoscopic mucosal resection 5 12
Outcome Alive 22 23 0.225b
Disease-free (at death or at present) 21 23 0.139b
aIncludes pancreatoduodenectomy and three cases of open–close laparotomy.
bChi-squared or Fisher's exact tests (when n < 5).
cMann–Whitney test.
Table 2 Comparison of pre- and postoperative diagnoses
Preoperative diagnosis Postoperative diagnosis, n Accuracy Overall accuracy
LGD HGD ADC
No-EUS LGD 21 2 6 72% 78%
HGD 1 1 3 20%
ADC 1 0 23 96%
EUS LGD 13 0 1a 93% 93%
HGD 0 1 1 50%
ADC 0 0 11 100%
aThe biopsy from this lesion was unsuitable for analysis and was subsequently diagnosed as ADC.
EUS, endoscopic ultrasound; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma.
Table 3 Comparison of sensitivity, specificity and predictive values
between the groups that did and did not receive endoscopic ultra-
sound (EUS)
Diagnosis Sensitivity Specificity PPV NPV
No-EUS LGD 91 77 72 93
HGD 50 93 20 98
ADC 72 96 96 86
EUS LGD 100 93 93 100
HGD 50 96 50 96
ADC 85 100 100 88
PPV, positive predictive value; NPV, negative predictive value; LGD, low-
grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarcinoma.
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Comparison of UGIE with EUS
The ability of EUS to correctly identify LGD, HGD or ADC at
endosonography was 85% (based upon the depth of invasion) and
from the material obtained for histological assessment was 92%.
The ability of UGIE to correctly identify LGD, HGD or ADC at
endoscopy was 62% (based upon the macroscopic appearance)
and from the material obtained for histological assessment was
60%. The difference in diagnostic accuracy following pathological
assessment was significant (P = 0.006).
Discussion
This study aimed to identify whether the addition of EUS to
standard tests investigating lesions of the ampulla affects the
accuracy of preoperative diagnosis. Near-perfect accuracy was
observed in patients undergoing EUS. The main difference
appeared to concern the strength of EUS to correctly identify
LGD, which was diagnosed correctly in every patient in the EUS
group. This contrasted with the no-EUS group, in which a diag-
nosis of LGD was responsible for the majority of incorrect diag-
noses (eight of 13). However, a diagnosis of ADC in the no-EUS
group was correct in all but one case. It appears that a preopera-
tive diagnosis of HGD should be interpreted with caution in view
of a high false negative rate observed in the present data and
by others.10 The management of early ampullary tumours is con-
troversial. Ampullectomy for HGD, Cis or T1 ADC has been
advocated over pancreatoduodenectomy because the former
facilitates decreases in procedural morbidity, mortality and
length of stay.11–14 The oncological outcome, however, is unsatis-
factory. Although limited series of patients undergoing endo-
scopic resection without recurrent disease, including patients
with T1 tumours, have been reported,12,13 other researchers have
reported that recurrent disease affects nearly 20% of patients.14
In the largest single series of patients (n = 435) undergoing pan-
creatoduodenectomy for ampullary neoplasms, 28% of patients
with T1 tumours were found to have lymph node metastases.11
The number of patients in the present series is too small to
support conclusions on the role of EUS in the accuracy and pre-
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Figure 1 Proposed algorithm for the investigation and subsequent management of a suspected lesion of the ampulla of Vater. EUS,
endoscopic ultrasound; EMR, endoscopic mucosal resection; LGD, low-grade dysplasia; HGD, high-grade dysplasia; ADC, adenocarci-
noma; R0, resection margin clear of disease
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dictive values of diagnosing and assessing HGD. The accuracy of
EUS in staging ‘T’ disease is thought to be lowest in T1 lesions
(0–100%) and to increase by T-stage to 45–100% for T2 lesions
and 75–100% for T3–T4 lesions.7,8,15–23 Thus, the tendency for
HGD to be understaged and for lymph node metastases to
develop in early tumours has clear implications for the manage-
ment of patients with a preoperative diagnosis of HGD or early
cancer. Although there is no agreed consensus on the manage-
ment of these lesions, for the reasons given, the present authors
advocate pancreatoduodenectomy. If a subject with HGD does
undergo endoscopic resection, thorough pathological sampling is
required. In patients in whom resection margins are incomplete
or in whom foci of invasive carcinoma are identified, pancre-
atoduodenectomy should be performed. In patients treated by
local resection, even with clear margins, surveillance must be per-
formed in view of the risk for recurrent disease.24
Evidence for the impact of EUS upon the management of
patients is seen in the significantly greater proportion of patients
treated by EMR in the EUS group.
The limitations of this study include the short follow-up of
patients with LGD in whom local resection was performed.
Although no patients have been found to exhibit recurrent disease
to date, this may reflect a lead time bias. Further limitations
include the low number of subjects with HGD or early tumours.
This reflects the nature and spectrum of this disease and is
observed in similar cohorts of presented cases. The role of EUS in
staging these lesions could be addressed by either a multi-
institution study or a systematic review.
According to the current findings, a simple diagnostic algorithm
is presented (Fig. 1). This can be summarized as: a diagnosis of
LGDmerits an investigationwithEUS; a diagnosis of HGDmust be
regardedwith caution regardless of the investigationmodality, and
a patient with a diagnosis of ADC does not benefit from EUS.
Patients with HGD should undergo pancreatoduodenectomy if
they are fit enough to do so and EMR if they are unfit for radical
resection. Endoscopic ultrasound could be used to assess local
invasion. Although EUS permits accurate local staging, it did not
assist in three patients in whom ADC was understaged and in
whomdistant peritoneal disease developed,who received inappro-
priate laparotomy and attempts at curative resection.
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